Clinical trials: Crohn's Disease, open to volunteers
Inflammatory Bowel Diseases (IBD), Crohn Disease
Longitudinal Registry of Difficult-to-Treat Inflammatory Bowel Disease
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refractory, structurally complicated, postoperative, perianal, pouch-related, or psychosocially complex disease.
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn Disease, Colitis, Ulcerative
- Trial name
- DTT-IBD (NCT07877649)
- Testing
- Routine IBD Management and Advanced-Therapy Exposure
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Crohn Disease (CD)
Glycan Supplementation on a Human Model of Crohn's Disease Initiation and Progression
The overall aim of this proof-of-concept trial is to investigate the effect of an orally administered glycan on the modulation of the dysregulation of host-microbiome interactions and its effect on the mucosal immune response.
- Trial name
- NCT06727253
- Testing
- Glycan
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- GLSMED Learning Health S.A.
Crohn's Disease
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
This is a phase 2, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants…
- Trial name
- CHROMA CD (NCT06958536)
- Testing
- brivekimig
- Where
- 66 sites in United States, Australia and 10 more
- Volunteers
- 99 people
- Sponsor
- Sanofi
Crohn Disease
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term…
- Trial name
- DUET ENCORE-CD (NCT07577843)
- Testing
- JNJ-78934804, Guselkumab
- Where
- 252 sites in United States, Argentina and 28 more
- Volunteers
- 460 people
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Bowel Diseases, Crohn Disease
Intestinal Ultrasound Guided Management in Inflammatory Bowel Disease
This randomized controlled trial evaluates whether adding point-of-care intestinal ultrasound (IUS) to standard of care changes clinical management in patients with inflammatory bowel disease (IBD).
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative
- Trial name
- NCT07775352
- Testing
- Intestinal ultrasound (IUS), Standard of care
- Where
- Thailand
- Volunteers
- 137 people
- Sponsor
- Mahidol University
Crohn's Disease
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
Background: Crohn s disease (CD) is an inflammatory bowel disease. It causes inflammation of the gut. Symptoms may include diarrhea, abdominal pain, fatigue, weight loss and malnutrition.
- Trial name
- NCT03167437
- Testing
- Vorinostat, Ustekinumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Crohn's Disease
Impact of Diet and Lifestyle Modification on the Intestinal Barrier Integrity in Crohn's Disease
The goal of this prospective interventional study is to evaluate whether the targeted avoidance of a particular food that was diagnosed to be disruptive for the intestinal barrier during confocal laser endomicroscopy (CLE)…
- Trial name
- LeakyDiet (NCT06719778)
- Testing
- Two-stage nutritional therapy concept
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Universität Duisburg-Essen
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
Prospective Evaluation of Flare Detection in IBD With Digital Biomarkers: Bring Your Own Device Study
The aim of this study is to identify HRV changes predictive of IBD flares using patient-own wearable devices in a large cohort supplemented by additional data layers including sleep parameters, step count and clinical data…
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn Disease (CD)
- Trial name
- BYOD (NCT07647640)
- Testing
- Wearing their own wearable device.
- Where
- 3 sites in Netherlands
- Volunteers
- 600 people
- Sponsor
- Maastricht University Medical Center
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Frailty
Immune Aging and Advanced Therapy Outcomes in Older Adults With IBD
The goal of this observational study is to learn whether signs of immune aging and frailty can help predict the balance of benefits and risks of advanced therapies in adults aged 60 years or older with inflammatory bowel disease…
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Frailty, Immunosenescence
- Trial name
- NCT07828886
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Crohn's Diseases
Effect of Intestinal Carriage of *Pilosibacter Rotomagensis* on Intestinal Inflammatory Activity
Crohn's disease is a chronic inflammatory condition that can affect the entire digestive tract. The terminal ileum is the segment most frequently involved, and approximately one-third of patients present with disease limited to…
- Trial name
- ProsPec (NCT07871383)
- Testing
- Microbiota suspension
- Where
- France
- Volunteers
- 116 people
- Sponsor
- University Hospital, Rouen
Enteric Hyperoxaluria
Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH).
A Phase II, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of TRA16 Administered Orally in Patients with Enteric Hyperoxaluria (EH).
- Trial name
- NCT07871669
- Testing
- TRA16
- Volunteers
- 30 people
- Sponsor
- Wuhan Kangfude Urolithiasis Research Institute Co., Ltd.
Inflammatory Bowel Diseases, Crohn's
The Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN)
The CIDsCaNN Network is being established with the major goals of identifying why IBD develops so commonly in children and adolescents living in Canada, and of determining the best treatment strategies for different types of IBD.
- Conditions
- Inflammatory Bowel Diseases, Crohn's, Ulcerative Colitis
- Trial name
- CIDsCaNN (NCT02308917)
- Where
- 12 sites in Canada
- Volunteers
- 2,400 people
- Sponsor
- The Hospital for Sick Children
Ulcerative Colitis, Healthy
Genome Analysis Across Populations in Inflammatory Bowel Disease
Objective: To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD within affected populations.
- Conditions
- Ulcerative Colitis, Healthy, Crohn Disease, Inflammatory Bowel Diseases
- Trial name
- NCT06042387
- Testing
- Blood or saliva sample collection
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Mount Sinai Hospital, Canada
Ulcerative Colitis, Crohn's Disease
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time.
- Trial name
- NCT06405087
- Testing
- Vedolizumab SC, No Intervention
- Where
- 47 sites in United States, Belgium and 12 more
- Volunteers
- 70 people
- Sponsor
- Takeda
Inflammatory Bowel Disease (IBD), Crohn's Disease
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
The goal of this observational study is to assess the feasibility and effectiveness of a remote monitoring digital health system on adherence, clinical outcomes, and healthcare utilization in patients with inflammatory bowel…
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
- Trial name
- MONITOR (NCT06750731)
- Testing
- Tappt
- Where
- 6 sites in United States
- Volunteers
- 200 people
- Sponsor
- Mercy Medical Center
Inflammatory Bowel Diseases, Crohn's Disease
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's…
- Trial name
- GARNET (NCT06226883)
- Testing
- MORF-057
- Where
- 225 sites in United States, Australia and 26 more
- Volunteers
- 385 people
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Crohn Disease
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely…
- Trial name
- NCT07483099
- Testing
- LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
- Where
- 70 sites in United States, Belgium and 8 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD).
- Conditions
- Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
- Trial name
- SHINE-ON (NCT04844606)
- Testing
- Mirikizumab
- Where
- 69 sites in United States, Austria and 14 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Crohn's Disease
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention.
- Trial name
- AMAY (NCT05509777)
- Testing
- Mirikizumab
- Where
- 81 sites in United States, Austria and 14 more
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
Family Members at INcreased-risk for Developing Inflammatory Bowel Disease
First-degree relatives of people with inflammatory bowel disease ("IBD," including Crohn's disease and ulcerative colitis) have an increased risk for developing IBD themselves.
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U), Indeterminate Colitis
- Trial name
- FIND-IBD (NCT06655415)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital